Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Peter Curtin

    Address9500 Gilman Drive #0960
    CA La Jolla 92093
    Phone858-822-6381
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Education and Training
      MD - SUNY Buffalo School of Medicine, Buffalo, NY
      Residency - North Carolina Memorial Hospital, Chapel Hill, NC
      Fellowship - UC San Francisco, School of Medicine, San Francisco, CA


      Collapse Research 
      Collapse Research Activities and Funding
      REGULATION OF ERYTHROPOIETIN GENE EXPRESSION
      NIH/NIDDK R29DK044956May 1, 1992 - Apr 30, 1997
      Role: Principal Investigator
      STRUCTURE &FUNCTION OF A UNIQUE B-THALASSEMIA DELETION
      NIH/NHLBI K11HL002060Apr 1, 1988 - May 31, 1993
      Role: Principal Investigator

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO, Ontiveros E, Purev E, Quiery A, Reddy VV, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Tibes R, Yang DT, Gregory K, Sundar H, Deininger M, Radich JP. NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2016 Dec; 14(12):1505-1512. PMID: 27956535.
        View in: PubMed
      2. Nguyen JC, Kubik MJ, Broome HE, Curtin P, Dell'Aquila ML, Wang HY. Successful treatment of both double minute of C-MYC and BCL-2 rearrangement containing large B-cell lymphoma with subsequent unfortunate development of therapy-related acute myeloid leukemia with t(3;3)(q26.2;q21). Pathol Res Pract. 2015 Nov; 211(11):883-91. PMID: 26300063.
        View in: PubMed
      3. O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, Curtin P, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H. Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw. 2014 Nov; 12(11):1590-610. PMID: 25361806.
        View in: PubMed
      4. Brammer JE, Stentz A, Gajewski J, Curtin P, Hayes-Lattin B, Kovacsovics T, Leis JF, Meyers G, Nemecek E, Subbiah N, Frires R, Palmbach G, Avraham GP, Slater S, Maziarz RT. Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. Biol Blood Marrow Transplant. 2015 Jan; 21(1):89-96. PMID: 25445641.
        View in: PubMed
      5. Wong-Sefdan I, Ale-Ali A, DeMoor PA, Martinez S, Curtin P, Lane T, Roeland E. Implementing inpatient, evidence-based, antihistamine-transfusion premedication guidelines at a single academic US hospital. J Community Support Oncol. 2014 Feb; 12(2):56-64. PMID: 24971406.
        View in: PubMed
      6. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin P, Cutler C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012 Aug; 18(8):1150-63. PMID: 22510384.
        View in: PubMed
      7. Wang HY, Thorson JA, Broome HE, Rashidi HH, Curtin P, Dell'Aquila ML. t(4;22)(q12;q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemia. Hum Pathol. 2011 Dec; 42(12):2029-36. PMID: 21676437.
        View in: PubMed
      8. Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, Williams S, Burris H, Faderl S, Estrov Z, Curtin P, Larson RA, Keck JG, Jones M, Meng L, Brown GL. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol. 2009; 2:20. PMID: 19439093.
        View in: PubMed
      9. Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM, Forman SJ, Petersen FB, Wade JC, Epner E, Bruno B, Bethge WA, Curtin P, Maloney DG, Blume KG, Storb RF. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant. 2008 Feb; 14(2):246-55. PMID: 18215785.
        View in: PubMed
      10. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin P, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008 Jan 1; 111(1):86-93. PMID: 17893227.
        View in: PubMed
      11. DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin P, Druker BJ, Heinrich MC. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006 Dec 1; 108(12):3674-81. PMID: 16902153.
        View in: PubMed
      12. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR, Moseley AB, Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005 May; 11(5):389-98. PMID: 15846293.
        View in: PubMed
      13. Leis JF, Primack SL, Schubach SE, Curtin P, Druker BJ, Maziarz RT. Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis. Haematologica. 2004 Sep; 89(9):ECR30. PMID: 15377482.
        View in: PubMed
      14. Leis JF, Stepan DE, Curtin P, Ford JM, Peng B, Schubach S, Druker BJ, Maziarz RT. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma. 2004 Apr; 45(4):695-8. PMID: 15160941.
        View in: PubMed
      15. Hayes-Lattin BM, Curtin P, Fleming WH, Leis JF, Stepan DE, Schubach S, Maziarz RT. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis. Bone Marrow Transplant. 2002 Sep; 30(5):279-85. PMID: 12209349.
        View in: PubMed
      16. Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, Luger SM, Ma MK, Ley TJ, DiPersio JF. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood. 2001 Jul 15; 98(2):266-71. PMID: 11435292.
        View in: PubMed
      17. Madan A, Lin C, Hatch SL, Curtin P. Regulated basal, inducible, and tissue-specific human erythropoietin gene expression in transgenic mice requires multiple cis DNA sequences. Blood. 1995 May 15; 85(10):2735-41. PMID: 7742534.
        View in: PubMed
      18. Curtin P, Kan YW. The inactive beta globin gene on a gamma delta beta thalassemia chromosome has a normal structure and functions normally in vitro. Blood. 1988 Mar; 71(3):766-70. PMID: 3345345.
        View in: PubMed